• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Antibiotics for Cancer Research
You are here: Product Lines > Cancer > Antibiotics for Cancer Research
 
Toolbar - View Selection
 
 Items 60-80 of 95 Page 4 of 5 Select Page: << 1 2 3 4 5  >>  
ALX-380-213 Revised 10-Dec-07
Kigamicin C
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-213-MC05   0.5 mg 320.00 USD Add To Cart
Product Specification
FORMULA: C41H47NO16
MW: 809.8
CAS NUMBER: 680571-51-1
SOURCE/HOST: Isolated from Amycolatopsis sp. MST-AS4724.
PURITY: ≥97% (HPLC)
APPEARANCE: Yellow powder.
SOLUBILITY: Soluble in 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.

Product Description
Antitumor antibiotic. Inhibits the growth of Gram-positive bacteria including MRSA.
Product Specific Literature References
Kigamicins, novel antitumor antibiotics. I. Taxonomy, isolation, physico-chemical properties and biological activities: S. Kunimoto, et al.; J. Antibiot. (Tokyo) 56, 1004 (2003) Abstract
Kigamicins, novel antitumor antibiotics. II. Structure determination: S. Kunimoto, et al.; J. Antibiot. (Tokyo) 56, 1012 (2003) Abstract
 
 
ALX-350-245 Revised 07-Apr-08
Lactacystin (native)
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Proteasome / Ubiquitin Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-245-MC01   0.1 mg 60.00 USD Add To Cart
ALX-350-245-MC05   0.5 mg 250.00 USD Add To Cart
ALX-350-245-M001   1 mg 445.00 USD Add To Cart
Product Specification
FORMULA: C15H24N2O7S
MW: 376.4
CAS NUMBER: 133343-34-7
SOURCE/HOST: Isolated from Streptomyces sp.
PURITY: ≥97% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in acetonitrile (20mg/ml), 100% ethanol (1mg/ml), methanol, DMSO (20mg/ml), dimethyl formamide (20mg/ml) or water (5mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Organic stock solutions are stable for 3 months when stored at -20°C. Subject to hydrolysis in aqueous buffers. We do not recommend storing the aqueous solutions for more than one day.
HANDLING: Protect from light.

Product Description

Cell permeable and irreversible proteasome inhibitor. Specifically inhibits 26S proteasome (MCP; multicatalytic proteinase complex). Blocks proteasome activity by targeting the catalytic β-subunit. Has no effect on serine or cysteine proteases. Induces apoptosis in human monoblast U937 cells. Also inhibits NF-κB activation by inhibiting IκB degradation. Inhibits the ubiquitin proteasome pathway in cell culture (IC50=10µM). Inhibits cathepsin A. Upregulates HSP70 and HSP22, suggesting an initial neuroprotective pathway.
Product Specific Literature References
Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells: S. Omura, et al.; J. Antibiot. 44, 116 (1991) Abstract
A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line: G. Fenteany, et al.; PNAS 91, 3358 (1994) Abstract
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells: S. Imajo-Ohmi, et al.; BBRC 217, 1070 (1995) Abstract
The neuritogenesis inducer lactacystin arrests cell cycle at both G0/G1 and G2 phases in neuro 2a cells: M. Katagiri, et al.; J. Antibiotics (Tokyo) 48, 344 (1995) Abstract
Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway: S. Mori, et al.; J. Biol. Chem. 270, 29447 (1995) Abstract; Full Text
Structure-activity relationships of lactacystin, the first non-protein neurotrophic factor: T. Nagamitsu, et al.; J. Antibiotics (Tokyo) 48, 747 (1995) Abstract
Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid: H. Tanaka, et al.; BBRC 216, 291 (1995) Abstract
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin: G. Fenteany, et al.; Science 268, 726 (1995) Abstract
Proteasome-dependent regulation of p21WAF1/CIP1 expression: M.V. Blagosklonny, et al.; BBRC 227, 564 (1996) Abstract
Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors: E. Fujita, et al.; BBRC 224, 74 (1996) Abstract
Degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in endoplasmic reticulum membranes is accelerated as a result of increased susceptibility to proteolysis: T.P. McGee, et al.; J.Biol. Chem. 271, 25630 (1996) Abstract; Full Text
Lactacystin increases LDL receptor level on HepG2 cells: H. Miura, et al.; BBRC 227, 684 (1996) Abstract
Proteasome pathway operates for the degradation of ornithine decarboxylase in intact cells: Y. Murakami, et al.; Biochem. J. 317, 77 (1996) Abstract; Full Text
Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol-linked protein in a pre-Golgi compartment: K. Oda, et al.; BBRC 219, 800 (1996) Abstract
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity: D. Qu, et al.; J. Biol. Chem. 271, 22791 (1996) Abstract; Full Text
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway: H. Yoshida, et al.; Cancer Res. 56, 2945 (1996) Abstract
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis: J. Delic, et al.; Br. J. Cancer 77, 1103 (1998) Abstract
Lactacystin, proteasome function, and cell fate: G. Fenteany & S.L. Schreiber; J. Biol. Chem. 273, 8545 (1998), (Review) Abstract; Full Text
Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells: P. Marambaud, et al.; Mol. Med. 4, 147 (1998) Abstract
The role of proteolysis during differentiation of Trypanosoma brucei from the bloodstream to the procyclic form: M.C. Mutomba & C.C. Wang; Mol. Biochem. Parasitol. 93, 11 (1998) Abstract
Lactacystin, a proteasome inhibitor: discovery and its application in cell biology: H. Tomoda & S. Omura; Yakugaku Zasshi 120, 935 (2000), Review Abstract
Lactacystin inhibits cathepsin A activity in melanoma cell lines: L. Kozlowski, et al.; Tumour Biol. 22, 211 (2001) Abstract
Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis: E.H. Yew, et al.; J. Neurochem. 94, 943 (2005) Abstract
Further Categories Containing This Product:
Heat Shock Proteins Other Products • Proteasome / Related Products • Antibiotics for Angiogenesis Research • NF-kB Pathway Inhibitors • Antibiotics - NF-kB Inhibitors • Antibiotics - Apoptosis Inducers & Inhibitors • Antitumor Antibiotics
 
 
ALX-350-260 Revised 11-Aug-08
Lactacystin (synthetic)
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Proteasome / Ubiquitin Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-260-MC01   0.1 mg 95.00 USD Add To Cart
ALX-350-260-M001   1 mg 730.00 USD Add To Cart
Product Specification
FORMULA: C15H24N2O7S
MW: 376.4
CAS NUMBER: 133343-34-7
SOURCE/HOST: Synthetic.
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in acetonitrile (20mg/ml), 100% ethanol (1mg/ml), methanol, DMSO (20mg/ml), dimethyl formamide (20mg/ml) or water (5mg/ml).
ACTIVITY: kobs/[I]=4’000M-1sec-1 versus 20S:PA28 complex.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Organic stock solutions are stable for 3 months when stored at -20°C. Subject to hydrolysis in aqueous buffers. We do not recommend storing aqueous solutions for more than one day.
HANDLING: Protect from light. Avoid freeze/thaw cycles.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Cell permeable and irreversible proteasome inhibitor. Specifically inhibits 26S proteasome (MCP; multicatalytic proteinase complex). Blocks proteasome activity by targeting the catalytic β-subunit. Has no effect on serine or cysteine proteases. Induces apoptosis in human monoblast U937 cells. Also inhibits NF-κB activation by inhibiting IκB degradation. Inhibits the ubiquitin proteasome pathway in cell culture (IC50=10µM).  Inhibits cathepsin A . Upregulates HSP70 and HSP22, suggesting an initial neuroprotective pathway.
Product Specific Literature References
Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells: S. Omura, et al.; J. Antibiot. 44, 113 (1991) Abstract
A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line: G. Fenteany, et al.; PNAS 91, 3358 (1994) Abstract
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells: S. Imajo-Ohmi, et al.; BBRC 217, 1070 (1995) Abstract
The neuritogenesis inducer lactacystin arrests cell cycle at both G0/G1 and G2 phases in neuro 2a cells: M. Katagiri, et al.; J. Antibiot. (Tokyo) 48, 344 (1995) Abstract
Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway: S. Mori, et al.; J. Biol. Chem. 270, 29447 (1995) Abstract; Full Text
Structure-activity relationships of lactacystin, the first non-protein neurotrophic factor: T. Nagamitsu, et al.; J. Antibiotics 48, 747 (1995) Abstract
Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid: H. Tanaka, et al.; BBRC 216, 291 (1995) Abstract
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin: G. Fenteany, et al.; Science 268, 726 (1995) Abstract
Proteasome-dependent regulation of p21WAF1/CIP1 expression: M.V. Blagosklonny, et al.; BBRC 227, 564 (1996) Abstract
Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors: E. Fujita, et al.; BBRC 224, 74 (1996) Abstract
Degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in endoplasmic reticulum membranes is accelerated as a result of increased susceptibility to proteolysis: T.P. McGee, et al.; J.Biol. Chem. 271, 25630 (1996) Abstract; Full Text
Lactacystin increases LDL receptor level on HepG2 cells: H. Miura, et al.; BBRC 227, 684 (1996) Abstract
Proteasome pathway operates for the degradation of ornithine decarboxylase in intact cells: Y. Murakami, et al.; Biochem. J. 317, 77 (1996) Abstract
Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol-linked protein in a pre-Golgi compartment: K. Oda, et al.; BBRC 219, 800 (1996) Abstract
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity: D. Qu, et al.; J. Biol. Chem. 271, 22791 (1996) Abstract; Full Text
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway: H. Yoshida, et al.; Cancer Res. 56, 2945 (1996) Abstract
Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation: A. Craiu, et al.; J. Biol. Chem. 272, 13437 (1997) Abstract; Full Text
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis: J. Delic, et al.; Br. J. Cancer 77, 1103 (1998) Abstract
Lactacystin, proteasome function, and cell fate: G. Fenteany & S.L. Schreiber; J. Biol. Chem. 273, 8545 (1998), (Review) Abstract; Full Text
The role of proteolysis during differentiation of Trypanosoma brucei from the bloodstream to the procyclic form: M.C. Mutomba, et al.; Mol. Biochem. Parasitol. 93, 11 (1998) Abstract
Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells: P. Marambaud, et al.; Mol. Med. 4, 147 (1998) Abstract
Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression: D. Kim, et al.; BBRC 254, 264 (1999) Abstract
Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells: H. Kitagawa, et al.; FEBS Lett. 443, 181 (1999) Abstract
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells: L.A. Pasquini, et al.; J. Neurosci. Res. 59, 601 (2000) Abstract
Proteasome inhibitors induce cytochrome c-caspase-3-like protease- mediated apoptosis in cultured cortical neurons: J.H. Qiu, et al.; J. Neurosci. 20, 259 (2000) Abstract
Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines: Y. Yamada, et al.; Eur. J. Haematol. 64, 315 (2000) Abstract
Lactacystin, a proteasome inhibitor: discovery and its application in cell biology: H. Tomoda & S. Omura; Yakugaku Zasshi 120, 935 (2000), Review Abstract
Lactacystin inhibits cathepsin A activity in melanoma cell lines: L. Kozlowski, et al.; Tumour Biol. 22, 211 (2001) Abstract
Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis: E.H. Yew, et al.; J. Neurochem. 94, 943 (2005) Abstract
Further Categories Containing This Product:
Proteasome / Related Products • NF-kB Pathway Inhibitors • Antibiotics for Angiogenesis Research • Antibiotics - NF-kB Inhibitors • Antibiotics - Apoptosis Inducers & Inhibitors • Antitumor Antibiotics
 
 
ALX-380-131 Revised 03-Sep-08 New product
Mensacarcin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-131-M001   1 mg 90.00 USD Add To Cart
ALX-380-131-M005   5 mg 360.00 USD Add To Cart
Product Specification
FORMULA: C21H24O9
MW: 420.4
SOURCE/HOST: Isolated from Streptomyces bottropensis.
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
IDENTITY: Identity determined by 1H-NMR.

Product Description

Antitumor compound. Has cytotoxic activity (TGI 1.3μM, NCI standard).
Product Specific Literature References
Towards a total synthesis of the new anticancer agent mensacarcin: synthesis of the carbocyclic core: L.F. Tietze, et al.; Chemistry 10, 5233 (2004) Abstract
 
 
ALX-380-109 Revised 01-Jul-08
Minocycline . hydrochloride
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics for Angiogenesis Research
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-109-M050   50 mg 30.00 USD Add To Cart
Product Specification
FORMULA: C23H27N3O7 . HCl
MW: 457.5 . 36.5
CAS NUMBER: 13614-98-7
MERCK INDEX: 14: 6202
RTECS: QI7630500
SOURCE/HOST: Semi-synthetic
APPEARANCE: Yellow crystalline solid.
SOLUBILITY: Soluble in water (50mg/ml, warm) or DMSO (7mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HAZARD: IRRITANT.

Product Description
Tetracycline derivative with antimicrobial activity. Inhibitor of angiogenesis, apoptosis and poly(ADP-ribose) polymerase-1 (PARP-1). Anti-inflammatory and neuroprotective.
Product Specific Literature References
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma: J.L. Frazier, et al.; J. Neurooncol. 64, 203 (2003) Abstract
Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases: J.S. Yao, et al.; Circ. Res. 95, 364 (2004) Abstract
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria: J. Wang, et al.; J. Biol. Chem. 279, 19948 (2004) Abstract
Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis: M. Castanares, et al.; BBRC 337, 663 (2005) Abstract
Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy: J.K. Krady, et al.; Diabetes 54, 1559 (2005) Abstract
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations: C.C. Alano, et al.; PNAS 103, 9685 (2006) Abstract
Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation: K. Maier, et al.; Neurobiol. Dis. 25, 514 (2007) Abstract
Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration: J.S. Yao, et al.; Neurochem. Int. 50, 524 (2007) Abstract
Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia: Y. Levkovitz, et al.; Brain Res. 1154, 154 (2007) Abstract
Further Categories Containing This Product:
Antibiotics - Apoptosis Inducers & Inhibitors • NOS Inhibitors (NOS Induction & Enzyme Activity) • Antibiotics - Nitric Oxide Pathway Modulators • COX Inhibitors • Antibiotics for Inflammation Research • Neuroactive Agents Other Products • PARP Inhibitors
 
 
ALX-380-023 Revised 19-Oct-07
Mitomycin C
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - DNA Replication Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-023-M005   5 mg 98.00 USD Add To Cart
ALX-380-023-M010   10 mg 185.00 USD Add To Cart
Product Specification
FORMULA: C15H18N4O5
MW: 334.3
CAS NUMBER: 50-07-7
MERCK INDEX: 14: 6215
RTECS: CN0700000
SOURCE/HOST: Isolated from Streptomyces caespitosus.
PURITY: ≥98%
APPEARANCE: Blue-violet crystals.
SOLUBILITY: Soluble in water or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Protect from light.
HAZARD: TOXIC. MAY BE CARCINOGENIC.

Product Description
Antitumor antibiotic. Inhibitor of DNA synthesis, nuclear division and cancer cells. DNA intercalating agent. Apoptosis inducer.
Product Specific Literature References
Mitomycin, a new antibiotic from Streptomyces. I: T. Hata, et al.; J. Antibiot. (Tokyo) 9, 141 (1956) Abstract
S.K. Carter & S.T. Crooke ; 'Mitomycin C. Current Status and New Developments', Academic Press, New York (1979)
Revised absolute configuration of mitomycin C. X-ray analysis of 1-N-(p-bromobenzoyl)mitomycin C: K. Shirahata & N. Hirayama; JACS 105, 7199 (1983)
Sequence-specific DNA damage induced by reduced mitomycin C and 7-N-(p- hydroxyphenyl)mitomycin C: K. Ueda and T. Komano; Nucl. Acids Res. 12, 6673 (1984) Abstract
Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA: M. Tomasz, et al.; Science 235, 1204 (1987) Abstract
The chemistry of DNA modification by antitumor antibiotics: J.F. Fisher & P.A. Aristoff; Prog. Drug Res. 32, 411 (1988) Abstract
DNA sequence specificity of mitomycin cross-linking: S.P. Teng, et al.; Biochemistry 28, 3901 (1989) Abstract
Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C: S. Kawasaki, et al.; J. Cancer Res. 83, 899 (1992) Abstract
Genetic evidence for an activator required for induction of pectin lyase in Erwinia carotovora subsp. carotovora by DNA-damaging agents: J.L. McEvoy, et al.; J. Bacteriol. 174, 5471 (1992) Abstract
Elevated DT-diaphorase activity and messenger RNA content in human non- small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl: A.M. Malkinson, et al.; Cancer Res. 52, 4752 (1992) Abstract
Mitomycins: J. Verweij, et al.; Cancer Chemother. Biol. Response Modif. 18, 46 (1999) Abstract
Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95- independent manner in human gastric adenocarcinoma cells: I.C. Park, et al.; Cancer Lett. 158, 125 (2000) Abstract
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis: C.T. Hsueh, et al.; Cancer Chemother. Pharmacol. 45, 389 (2000) Abstract
DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling: A.R. Tee & C.G. Proud; Oncogene 19, 3021 (2000) Abstract
Re-evaluation of tumor-specific cytotoxicity of mitomycin C, bleomycin and peplomycin: M. Sasaki, et al.; Anticancer Res. 26, 3373 (2006) Abstract
Activation of the S phase DNA damage checkpoint by mitomycin C: E. Mladenov, et al.; J. Cell. Physiol. 211, 468 (2007) Abstract
Further Categories Containing This Product:
DNA Replication Inhibitors • Antitumor Agents (Apoptosis Inducers) • Antibiotics - Apoptosis Inducers & Inhibitors • Antitumor Antibiotics • Antitumor Agents (DNA Interaction & Gene Regulation)
 
 
ALX-804-624 Revised 20-Jun-05
Monoclonal Antibody to Doxorubicin (MAD11)
Add to Clipboard
SYNONYMS anti-DXR MAb (MAD11)
anti-14-Hydroxydaunomycin MAb (MAD11)
anti-Adriamycin MAb (MAD11)
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-624-C100   100 µg 320.00 USD Add To Cart
Product Specification
CLONE: MAD11
ISOTYPE: Mouse IgG2
CONCENTRATION:   
FORMULATION: Liquid. Purified antibody containing 150mM sodium chloride and 0.02% sodium azide, pH 7.4.
IMMUNOGEN: Doxorubicin-BSA.
SPECIFICITY: Recognizes anthracycline compounds including doxorubicin analogs and derivatives.
APPLICATION: ELISA
Immunohistochemistry
Functional Application: In vivo antidotic effect.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: +4°C
HANDLING: Do not freeze.
Product Specific Literature References
Monoclonal antibodies against doxorubicin: A. Balsari, et al.; Int. J. Cancer 42, 798 (1988) Abstract
A new monoclonal antibody recognizing anthracyclinic molecule: A. Balsari, et al.; Anticancer Res. 10, 129 (1990) Abstract
Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin: A. Balsari, et al.; Int. J. Cancer 47, 889 (1991) Abstract
An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug: A. Sardini, et al.; Int. J. Cancer 50, 617 (1992) Abstract
Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies: A.L. Balsari, et al.; FASEB J. 8, 226 (1994) Abstract
Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice: D. Morelli, et al.; Cell Biophys. 24-25, 119 (1994) Abstract
Relevance of antibody valency in EGF receptor modulation: D. Morelli, et al.; Scand. J. Immunol. 39, 453 (1994) Abstract
Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice: D. Morelli, et al.; Cancer Res. 56, 2082 (1996) Abstract
Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats: R. Cece, et al.; Lab. Invest. 75, 601 (1996) Abstract
Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice: D. Morelli, et al.; Br. J. Cancer 75, 656 (1997) Abstract
Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice: A. Balsari, et al.; Br. J. Cancer 85, 1964 (2001) Abstract
Role of proliferation in HER2 status predicted response to doxorubicin: M. Campiglio, et al.; Int. J. Cancer 105, 568 (2003) Abstract
Further Categories Containing This Product:
Monoclonal Antibodies • Topoisomerases Other Products • Antibiotics - Topoisomerase Inhibitors • Cancer Other Products
 
 
ALX-380-233 Revised 08-Apr-08
Neoantimycin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antitumor Antibiotics
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-380-233-MC05   0.5 mg 360.00 USD Add To Cart
Product Specification
FORMULA: C36H46N2O12
MW: 698.8
CAS NUMBER: 22862-63-1